Celldex Boldly Goes Alone in Pivotal Trial of Rindopepimut
As expected, Celldex Therapeutics Inc. launched the randomized, double-blind, controlled Phase III trial of its cancer vaccine candidate rindopepimut (formerly CDX-110) in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST